Pulmonary autograft versus aortic homograft for aortic valve replacement: Interim results from a prospective randomized trial

Citation
L. Aklog et al., Pulmonary autograft versus aortic homograft for aortic valve replacement: Interim results from a prospective randomized trial, J HEART V D, 9(2), 2000, pp. 176-188
Citations number
38
Categorie Soggetti
Cardiovascular & Respiratory Systems
Journal title
JOURNAL OF HEART VALVE DISEASE
ISSN journal
09668519 → ACNP
Volume
9
Issue
2
Year of publication
2000
Pages
176 - 188
Database
ISI
SICI code
0966-8519(200003)9:2<176:PAVAHF>2.0.ZU;2-G
Abstract
Background and aim of the study: Although pulmonary autografts offer advant ages over aortic homografts, they may also carry additional risks. We revie wed the interim results of a prospective randomized trial of autograft vers us homograft aortic valve replacement (AVR) to determine if the greater com plexity of the autograft insertion is justified, particularly with regard t o time-related hemodynamic function. Methods: A total of 182 patients (82% male, 18% female; mean age 37.2 +/- 1 4.3 years; range: 2-64 years) with isolated aortic valve disease were rando mized to pulmonary autograft (group A, n = 97) or aortic homograft (group H , n = 85); 42% had previous aortic valve surgery and 19% had native or pros thetic valve endocarditis. Follow up included annual outpatient visits and echocardiography. Results: Autograft AVR required longer cross-clamp (41%) and bypass (43%) t imes, but did not result in significantly more bleeding, longer recovery or more complications. One 30-day death occurred in group A (1%), and three d eaths in group H (4%). Median follow up was 33.9 months (range: 1-61 months ). There was one late death in each group, three reoperations in group A (a ll for pulmonary homografts), and three in group H (including two aortic ho mograft reoperations, both in children). There were no autograft reoperatio ns. There were no other valve-related events. At 48 months, actuarial survi val and reoperation-free survival rates were 97.8% and 94.2% in group A, an d 95.3% and 87.7% in group H (p = NS). Echocardiography showed near-perfect function in all autografts, but early signs of subclinical dysfunction in many homografts. Conclusion: Both autograft and homograft AVR are safe and produce good inte rmediate-term results. Early homograft degeneration appears to favor autogr afts in children. The echocardiographic findings may translate into superio r long-term autograft durability and hemodynamics.